1Melnick A,Licht JD.Deconswcting a disease:RARalpha,its fusion partners,and their roles in thepathogenesis of acute promyelocytic leukemia[J].Blood,1999,93:3167-3215.
2Wang ZY,Chen Z.Differentiation and apoptosis induction therapy in acute promyelocytic leukemia[review][J].Lancet Oncol,2000,1:101-106.
3de Botton S,Chevret S,Coiteux V,et al.Early onset of chemotherapy canreduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low blood cell counts:results from APL 93 trial[J].Leukemia,2003,17:339-342.
4Sanz MA,Martin G,Lo Coco F.Choice of chemotherapy in induction,consolidation and maintenance in acute promyelocytic leukemia[J].Baillieres Best Pract Res Clin Haematol,2003,16:433-451.
5Ghavamzadeh A,Alimoghaddaml K,Ghaffari S H,et al.Treatment of acute promyelocytic leukemia with arsenic trioxidewithout ATRA and/or chemotherapy[J].Annals of Oncology,2006,17:131-134.
6Chen Z,Chen GQ,Shen ZX,et al.Treatment of acute promyelocytic leukemia with arsenic trioxide compounds:in vitro and in vivo studies[review][J].Semin Hematol,2001,38:26-36.
7Cheson BD,Bennett JM,Kopecky K,et al.Revised recommendations of the International Working Group for Diagnosis,Standardization of Response Criteria,Treatment Outcomes,and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia[J].J Clin Oncol,2003,21:4642-4649.
8Sanz M,Martin G,Gonzalez M,et al.Riskadapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monoche-motherapy:a multicenter study by the PETHEMA group[J].Blood,2004,103:1237-1243.
9Feneaux P,Chadtang C,Cherret S,et al.A randomized comparison of all-tranns retinoic acid followed by chemotherapy andATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promylocytic leukemia[J].Blood,1999,94:1192-1200.
10Fenaux P,Chevret S,Guerci A,et al.Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia[J].European APL Group.Leukemia.2000,14:1371-1377.
1Douer D. The epidemiology of acute promyelocytic leukae- mia[J]. Best Pract Res Clin Haematol, 2003,16 (3) : 357- 367.
2Avvisati G,Lo-Coeo F,Paoloni FP,et al. AIDA 0493 pro- tocol for newly diagnosed acute promyeloeytie leukemia: very long-term results and role of maintenance[J]. Blood, 2011,117(18) :4716-4725.
3Dai CW,Zhang GS,Shen JK,et al. Use of all-trans retino- ic acid in combination with Arsenic trioxide for remission induction in patients with newly diagnosed acute promye- locytic leukemia and for consolidation/maintenance in CR patients[J]. Acta Haematol, 2009,121 ( 1 ) : 1-8.
4Creutzig U, Zimmermann M,Dworzak M, et al. Favoura- ble outcome of patients with childhood acute promyelo- cytic leukaemia after treatment with reduced cumulative anthracycline doses[J]. Br J Haematol, 2010,149 (3) : 399- 409.
5Roxo-Junior P, Silva J, Andrea M, et al. A family history of serious complications due to BCG vaccination is a tool for the early diagnosis of severe primary immunodeficien- cy[J]. Ital J Pediatr,2013,39(1) :54-58.
6Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyeloeytic leukemia arising after multiple sclerosis[J]. Haematologi- ca,2011,96(4) :621-625.
